WO2007054279A3 - Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions - Google Patents

Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions Download PDF

Info

Publication number
WO2007054279A3
WO2007054279A3 PCT/EP2006/010693 EP2006010693W WO2007054279A3 WO 2007054279 A3 WO2007054279 A3 WO 2007054279A3 EP 2006010693 W EP2006010693 W EP 2006010693W WO 2007054279 A3 WO2007054279 A3 WO 2007054279A3
Authority
WO
WIPO (PCT)
Prior art keywords
adjuvants
pharmaceutical compositions
dinucleotides
conjugates
cyclic
Prior art date
Application number
PCT/EP2006/010693
Other languages
French (fr)
Other versions
WO2007054279A2 (en
WO2007054279A8 (en
Inventor
Thomas Ebensen
Michael Morr
Carlos A Guzman
Original Assignee
Helmholtz Infektionsforschung
Thomas Ebensen
Michael Morr
Carlos A Guzman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Infektionsforschung, Thomas Ebensen, Michael Morr, Carlos A Guzman filed Critical Helmholtz Infektionsforschung
Priority to AU2006312688A priority Critical patent/AU2006312688B2/en
Priority to US12/092,747 priority patent/US9597391B2/en
Priority to EP06806710.7A priority patent/EP1959989B1/en
Priority to CA2624903A priority patent/CA2624903C/en
Publication of WO2007054279A2 publication Critical patent/WO2007054279A2/en
Publication of WO2007054279A8 publication Critical patent/WO2007054279A8/en
Publication of WO2007054279A3 publication Critical patent/WO2007054279A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
PCT/EP2006/010693 2005-11-08 2006-11-08 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions WO2007054279A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006312688A AU2006312688B2 (en) 2005-11-08 2006-11-08 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
US12/092,747 US9597391B2 (en) 2005-11-08 2006-11-08 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
EP06806710.7A EP1959989B1 (en) 2005-11-08 2006-11-08 Cyclic dinucleotides as adjuvants for therapeutic or prophylactic vaccination
CA2624903A CA2624903C (en) 2005-11-08 2006-11-08 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05024266A EP1782826A1 (en) 2005-11-08 2005-11-08 PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
EP05024266.8 2005-11-08

Publications (3)

Publication Number Publication Date
WO2007054279A2 WO2007054279A2 (en) 2007-05-18
WO2007054279A8 WO2007054279A8 (en) 2007-07-12
WO2007054279A3 true WO2007054279A3 (en) 2007-08-30

Family

ID=35840427

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2006/010699 WO2007054283A2 (en) 2005-11-08 2006-11-08 Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions
PCT/EP2006/010693 WO2007054279A2 (en) 2005-11-08 2006-11-08 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/010699 WO2007054283A2 (en) 2005-11-08 2006-11-08 Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions

Country Status (7)

Country Link
US (2) US8257734B2 (en)
EP (3) EP1782826A1 (en)
AU (2) AU2006312688B2 (en)
CA (2) CA2624905C (en)
ES (1) ES2390895T3 (en)
HK (1) HK1121396A1 (en)
WO (2) WO2007054283A2 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US9061048B2 (en) * 2010-12-15 2015-06-23 The Regents Of The University Of California Cyclic di-AMP induction of type I interferon
JP5650780B2 (en) 2012-04-04 2015-01-07 日東電工株式会社 Vaccine composition
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanoparticles for treatment of allergy
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
ES2718910T3 (en) 2012-12-13 2019-07-05 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemicals and methods for their preparation and use
KR102061752B1 (en) * 2012-12-19 2020-01-02 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
RU2685933C2 (en) 2013-02-05 2019-04-23 Нитто Денко Корпорейшн Anticancer vaccine composition containing peptide wt1 for transdermal administration
CA2840988A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
CN103961307B (en) 2013-02-05 2019-11-29 日东电工株式会社 For percutaneous administration of with WT1 peptide cancer vaccine composition
IN2014CH00393A (en) 2013-02-05 2015-04-03 Nitto Denko Corp
CA2908154C (en) * 2013-04-29 2023-11-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
JP2016518140A (en) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Method for inducing cyclic dinucleotide of type I interferon
WO2014189806A1 (en) * 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
DK2996473T3 (en) 2013-05-18 2019-11-04 Aduro Biotech Inc COMPOSITIONS AND METHODS FOR ACTIVATING THE "INTERFERON GENE STIMULATOR" -DENGED SIGNAL
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
US10092644B2 (en) 2013-11-22 2018-10-09 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
WO2015133411A1 (en) 2014-03-03 2015-09-11 ヤマサ醤油株式会社 Crystalline 3',5'-cyclic diguanylic acid
WO2015137469A1 (en) 2014-03-14 2015-09-17 ヤマサ醤油株式会社 Inclusion compound of 3',5'-cyclicdiadenylic acid, and method for producing same
SG11201609021QA (en) * 2014-06-04 2016-11-29 Glaxosmithkline Ip Dev Ltd Cyclic di-nucleotides as modulators of sting
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
SG11201706756VA (en) * 2015-03-10 2017-09-28 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
BR112018002757A8 (en) 2015-08-13 2023-04-11 Merck Sharp & Dohme COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS FOR INDUCING AN IMMUNE RESPONSE, FOR INDUCING TYPE I INTERFERON PRODUCTION, AND FOR TREATMENT OF A DISORDER
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
RU2020113165A (en) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед CYCLIC PURINE DINUCLEOTIDES AS STING MODULATORS
WO2017106740A1 (en) * 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
US20190105381A1 (en) 2016-03-16 2019-04-11 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer
CA3017524A1 (en) 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
SG11201808621TA (en) 2016-04-07 2018-10-30 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
JP2019510802A (en) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Heterocyclic amides useful as protein modulators
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
US10696985B1 (en) 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CN110036001B (en) 2016-10-04 2022-03-22 默沙东公司 Benzo [ b ] thiophene compounds as STING agonists
WO2018068132A1 (en) 2016-10-11 2018-04-19 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof
JOP20170192A1 (en) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
CN106928298B (en) * 2017-03-13 2021-10-22 杭州星鳌生物科技有限公司 Structural composition of cyclic dinucleotide cGAMP derivative, preparation method and application of cyclic dinucleotide cGAMP derivative in tumor resistance
JP7160833B2 (en) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． anti-SIRP alpha antibody
KR20200006972A (en) 2017-04-14 2020-01-21 톨나인, 인크. Immunomodulatory polynucleotides, antibody conjugates thereof, and methods of use thereof
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
WO2019023459A1 (en) * 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
MA49773A (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO AGONISTS [B
AU2018311966A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Benzo[b]thiophene sting agonists for cancer treatment
AU2018336791A1 (en) 2017-09-19 2020-03-12 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor T cell therapy and uses thereof
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
EP3692034A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
EP3691640A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Methods for administering sting agonists
MX2020004858A (en) 2017-11-10 2020-10-01 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using.
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
KR102492187B1 (en) * 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3' cyclic dinucleotides with phosphonate linkages that activate STING adapter proteins
EP3737413A4 (en) * 2018-01-09 2021-12-15 N-Fold Llc Immune modulation
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
CN111971277B (en) 2018-04-03 2023-06-06 默沙东有限责任公司 Benzothiophenes and related compounds as STING agonists
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2020027309A1 (en) * 2018-08-03 2020-02-06 国立大学法人東京大学 Intranasal vaccine that induces cellular immunity
AR114551A1 (en) 2018-08-13 2020-09-16 Alnylam Pharmaceuticals Inc COMPOSITIONS OF hdRNA AGENTS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS FOR THEIR USE
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
US20220008346A1 (en) 2018-10-30 2022-01-13 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
TW202104214A (en) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 Chemical compounds
AU2020267486A1 (en) 2019-05-09 2021-11-11 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as STING modulators
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
EP3785719A1 (en) 2019-08-28 2021-03-03 Helmholtz-Zentrum für Infektionsforschung GmbH New use of cyclic dinucleotides
TW202128775A (en) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 Pd-l1 inhibitor - tgfβ inhibitor bispecific drug moieties
CN113058033A (en) * 2019-12-16 2021-07-02 远大赛威信生命科学(南京)有限公司 Pharmaceutical composition for preventing and treating hepatitis B and application thereof
MX2022010515A (en) 2020-02-28 2022-11-14 Tallac Therapeutics Inc Transglutaminase-mediated conjugation.
WO2021198064A1 (en) * 2020-03-31 2021-10-07 Consejo Superior De Investigaciones Científicas In vitro method for detection of infections caused by pseudomonas aeruginosa
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
EP3936514B1 (en) * 2020-07-10 2023-05-24 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with an alkenylene
PE20231947A1 (en) 2020-11-09 2023-12-05 Takeda Pharmaceuticals Co ANTIBODY AND DRUG CONJUGATES
TW202241516A (en) 2020-12-17 2022-11-01 美商杜夫特學院信託管理公司 Fap-activated radiotheranostics, and uses related thereto
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
US20230414763A1 (en) 2022-03-04 2023-12-28 Massachusetts Institute Of Technology Transmucosal amphiphile-protein conjugate vaccine
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US5547941A (en) * 1991-07-18 1996-08-20 Farmitalia Carlo Erba S.R.L. Cyclic dinucleoside diphosphorothioates, related compounds and pharmaceutical compositions
US20040097719A1 (en) * 2002-10-24 2004-05-20 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
WO2004108634A2 (en) * 2003-06-11 2004-12-16 Celares Gmbh Reagents for modifying biopharmaceuticals, the use and production thereof
WO2005030186A2 (en) * 2003-07-28 2005-04-07 Univ Maryland Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
WO2005087238A2 (en) * 2004-03-15 2005-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3420116A1 (en) * 1984-05-30 1985-12-05 Bayer Ag, 5090 Leverkusen IMMUNTIMULATING AGENTS
AU3938893A (en) * 1992-03-27 1993-11-08 Abbott Laboratories Haptens, tracers, immunogens and antibodies for quinoline
WO2001045727A2 (en) * 1999-12-20 2001-06-28 New Pharma Research Sweden Ab Stabilized veterinary compositions comprising more than one antiviral agent
US20020177715A1 (en) * 2000-08-31 2002-11-28 Pesci Everett C. Novel autoinducer molecules and uses therefor
GB0030729D0 (en) * 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
FR2822849B1 (en) * 2001-03-27 2003-12-12 Usinor VACUUM PROCESSING ENCLOSURE, IN PARTICULAR FOR STEEL DECARBURIZATION
GB0116312D0 (en) * 2001-07-04 2001-08-29 Univ Nottingham "Compositions containing N-acyl homoserine lactones"
PT1490106E (en) 2002-04-04 2008-09-05 Helmholtz Zentrum Fur Infektionschung Gmbh Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
EP1382352A1 (en) 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein conjugates and the use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US5547941A (en) * 1991-07-18 1996-08-20 Farmitalia Carlo Erba S.R.L. Cyclic dinucleoside diphosphorothioates, related compounds and pharmaceutical compositions
US20040097719A1 (en) * 2002-10-24 2004-05-20 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
WO2004108634A2 (en) * 2003-06-11 2004-12-16 Celares Gmbh Reagents for modifying biopharmaceuticals, the use and production thereof
WO2005030186A2 (en) * 2003-07-28 2005-04-07 Univ Maryland Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
WO2005087238A2 (en) * 2004-03-15 2005-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
WO2005089777A1 (en) * 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EBENSEN ET AL: "The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 25, no. 8, 23 January 2007 (2007-01-23), pages 1464 - 1469, XP005829883, ISSN: 0264-410X *
LINK CLAUDIA ET AL: "The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity.", EUROPEAN JOURNAL OF IMMUNOLOGY. MAR 2004, vol. 34, no. 3, March 2004 (2004-03-01), pages 899 - 907, XP002370290, ISSN: 0014-2980 *
ROSS P ET AL: "THE CYCLIC DIGUANYLIC ACID REGULATORY SYSTEM OF CELLULOSE SYNTHESIS IN ACETOBACTER-XYLINUM CHEMICAL SYNTHESIS AND BIOLOGICAL ACTIVITY OF CYCLIC NUCLEOTIDE DIMER TRIMER AND PHOSPHOTHIOATE DERIVATIVES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 265, no. 31, 1990, pages 18933 - 18943, XP002329128, ISSN: 0021-9258 *
VAJDY MICHAEL ET AL: "Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.", IMMUNOLOGY AND CELL BIOLOGY. DEC 2004, vol. 82, no. 6, December 2004 (2004-12-01), pages 617 - 627, XP002370291, ISSN: 0818-9641 *

Also Published As

Publication number Publication date
AU2006312692B2 (en) 2013-05-02
HK1121396A1 (en) 2009-04-24
ES2390895T3 (en) 2012-11-19
WO2007054279A2 (en) 2007-05-18
CA2624905A1 (en) 2007-05-18
AU2006312688A1 (en) 2007-05-18
AU2006312688B2 (en) 2013-05-16
WO2007054283A2 (en) 2007-05-18
US9597391B2 (en) 2017-03-21
US20080286296A1 (en) 2008-11-20
EP1959990A2 (en) 2008-08-27
EP1782826A1 (en) 2007-05-09
EP1959990B1 (en) 2012-07-18
AU2006312692A1 (en) 2007-05-18
CA2624903C (en) 2017-02-28
WO2007054279A8 (en) 2007-07-12
WO2007054283A3 (en) 2007-08-09
EP1959989B1 (en) 2014-01-01
CA2624903A1 (en) 2007-05-18
EP1959989A2 (en) 2008-08-27
US8257734B2 (en) 2012-09-04
US20090169609A1 (en) 2009-07-02
CA2624905C (en) 2015-04-28

Similar Documents

Publication Publication Date Title
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2007059931A8 (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
WO2018033254A3 (en) Rna for cancer therapy
WO2006099169A3 (en) Novel liposome compositions
TW200637614A (en) Bendamustine pharmaceutical compositions
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
MX2013004817A (en) Inflammatory disease.
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2009156960A3 (en) Novel adjuvant compositions
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
MY129263A (en) Vaccine composition
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MY143795A (en) Tetrahydropyridoindole derivatives
WO2005063201A3 (en) Liposomes and liposomal compositions for vaccination and drug delivery
WO2008087367A3 (en) Substituted (phenylthiazolyl)-phenyl-propan-1-one and (phenyloxazodyl)-phenyl-propan-1-one derivatives, preparations and uses of same
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
UA105210C2 (en) Anti-cancer vaccine and use thereof
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2006014292A3 (en) Oral vaccine for borrelia
UA94036C2 (en) Bendamustine pharmaceutical compositions for lyophilisation
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2008030818A3 (en) Novel liposome compositions
WO2009135199A3 (en) Vaccine compositions and methods
TW200716226A (en) Compositions comprising actinidia and methods of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2624903

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006312688

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12092747

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 958/MUMNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006312688

Country of ref document: AU

Date of ref document: 20061108

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006312688

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006806710

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06806710

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006806710

Country of ref document: EP